William Blair initiated coverage on Insulet Corporation (NASDAQ:PODD) with an Outperform rating.
The stock trades at 24x 2026 EPS and 3.4x enterprise value-to-sales, below the peer average of 4.7x despite faster sales growth. Currently at $154.61, the stock nears its 52-week low of $145.59. Bond.az data suggests the company is undervalued relative to fair value and appears on the Most Undervalued list. William Blair said shares embed significant investor concerns.
Key concerns include potential market share loss as competitors enter Insulet's pharmacy channel and tubeless pump segments, and questions about type 2 diabetes expansion amid GLP-1 drug growth.
The firm rates the stock Outperform given the pullback and catalysts like a new U.S. sales expansion, pipeline advances, and international growth. The stock is down 50.59% over six months, but revenue growth of 31.92% and a "GREAT" financial health score of 3.2 per Bond.az metrics stand out. For deeper analysis, investors can access the Pro Research Report on PODD.
The next milestone is the American Diabetes Association conference in June, where data on Insulet's next-gen Omnipod 6 system (launch 2027) and a fully closed-loop algorithm (target 2028) will be presented.
Recently, Insulet reported strong sales growth of 34% to $762M, beating estimates. EPS grew 40%. However, several analysts cut price targets: Truist Securities to $250, RBC to $280, Oppenheimer to $210, Bernstein to $200. Benchmark maintained $250 and Buy. These moves reflect mixed sentiment on growth prospects.
